首頁
即時
堰塞湖溢流
熱門
政治
社會
娛樂
體育
財經
長照
生活
即時新聞
財經政策
台股
熱門概念股
焦點股
美股
基金
產業動態
房市
首頁
即時
堰塞湖溢流
熱門
政治
社會
娛樂
體育
財經
長照
生活
國際
數位專題
合作友站
民視論壇
FTV財經
>
陳健仁
疫苗研發臨床試驗需要3千人 陳健仁：進度順遂
«
‹
1
›
»
;%20}%20.cls-2%20{%20fill:%20%23fff;%20}%20.cls-2,%20.cls-3%20{%20fill-rule:%20evenodd;%20}%20.cls-3%20{%20fill-opacity:%20.3;%20}%20%3c/style%3e%3cmask%20id='mask'%20x='8'%20y='19'%20width='10'%20height='15'%20maskUnits='userSpaceOnUse'%3e%3cg%20id='mask-2'%3e%3cpolygon%20id='path-1'%20class='cls-2'%20points='18%2019%208%2019%208%2034.1%2018%2034.1%2018%2019'/%3e%3c/g%3e%3c/mask%3e%3c/defs%3e%3c!--%20Generator:%20Adobe%20Illustrator%2028.7.1,%20SVG%20Export%20Plug-In%20.%20SVG%20Version:%201.2.0%20Build%20142)%20--%3e%3cg%3e%3cg%20id='_圖層_1'%20data-name='圖層_1'%3e%3cg%20id='Web版'%3e%3cg%20id='_財經-首頁'%20data-name='財經-首頁'%3e%3cg%20id='revers_btn'%3e%3cpath%20id='Rectangle'%20class='cls-3'%20d='M12,0H0v53.1h12c7.2,0,13-5.8,13-13V13C25,5.8,19.2,0,12,0Z'/%3e%3cg%20id='_x2D_Previous_x5F_btn'%3e%3cg%20class='cls-1'%3e%3cpath%20id='Fill-1'%20class='cls-2'%20d='M16.6,33.7c.1-.2.2-.5.2-.8s0-.4-.1-.6c0-.2-.2-.3-.4-.4l-6.3-4.3,6.3-4.3c.1,0,.3-.2.4-.4,0-.2.1-.4.1-.6,0-.3,0-.6-.2-.8-.1-.2-.3-.3-.5-.3s-.2,0-.3,0l-7,4.9c-.4.3-.7.8-.7,1.4v.2c0,.6.2,1.1.7,1.4l7,4.9c0,0,.2,0,.3,0,.2,0,.4-.1.5-.3'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
;%20}%20.cls-2%20{%20fill:%20%23fff;%20}%20.cls-2,%20.cls-3%20{%20fill-rule:%20evenodd;%20}%20.cls-3%20{%20fill-opacity:%20.3;%20}%20%3c/style%3e%3cmask%20id='mask'%20x='8'%20y='19.6'%20width='10'%20height='14.7'%20maskUnits='userSpaceOnUse'%3e%3cg%20id='mask-2'%3e%3cpolygon%20id='path-1'%20class='cls-2'%20points='8%2019.6%2018%2019.6%2018%2034.3%208%2034.3%208%2019.6'/%3e%3c/g%3e%3c/mask%3e%3c/defs%3e%3c!--%20Generator:%20Adobe%20Illustrator%2028.7.1,%20SVG%20Export%20Plug-In%20.%20SVG%20Version:%201.2.0%20Build%20142)%20--%3e%3cg%3e%3cg%20id='_圖層_1'%20data-name='圖層_1'%3e%3cg%20id='Web版'%3e%3cg%20id='_財經-首頁'%20data-name='財經-首頁'%3e%3cg%20id='next_btn'%3e%3cpath%20id='Rectangle'%20class='cls-3'%20d='M14,.2h12v53.1h-12c-7.2,0-13-5.8-13-13V13.2C1,6,6.8.2,14,.2Z'/%3e%3cg%20id='Group-3'%3e%3cg%20class='cls-1'%3e%3cpath%20id='Fill-1'%20class='cls-2'%20d='M9.4,34c-.1-.2-.2-.5-.2-.8s0-.4.1-.6c0-.2.2-.3.4-.4l6.3-4.2-6.3-4.2c-.1,0-.3-.2-.4-.4,0-.2-.1-.4-.1-.6,0-.3,0-.6.2-.8.1-.2.3-.3.5-.3s.2,0,.3,0l7,4.8c.4.3.7.8.7,1.4v.2c0,.6-.2,1.1-.7,1.4l-7,4.8c0,0-.2,0-.3,0-.2,0-.4-.1-.5-.3'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)